Skip NavigationSkip to Content
CANCER IMMUNOLOGY AND IMMUNOTHERAPY: Delivering the Promise

October 9-10, 2014
Top Right Header
Spacer image Spacer
Spacer CANCER IMMUNOLOGY AND IMMUNOTHERAPY: Delivering the Promise - Agenda

Final Agenda

Thursday, October 9

8:30 a.m. Robert Wiltrout, Steven Rosenberg - Introductions
Adoptive Cell Therapies
9:00 a.m. Steven Rosenberg, National Cancer Institute, Bethesda, MD
The Curative Potential of Cell Transfer Immunotherapy
9:30 a.m. Nicholas Restifo, National Cancer Institute, Bethesda, MD
Building a Better Anti-Tumor T Cell
10:00 a.m. Dirk Busch, Technische Universität München, München, Germany
Clinical Purification of T Cell Subsets Most Effective for Adoptive Immunotherapy
10:30 a.m. BREAK
11:00 a.m. Ton Schumacher, The Netherlands Cancer Institute, Amsterdam
Linking Cancer Exomes to Cancer Immunotherapy
11:30 a.m. Philip Greenberg, University of Washington, Seattle, WA
Engineering T Cells to be Effective in Tumor Therapy
12:00 p.m. Patrick Hwu, MD Anderson Cancer Center, Houston, TX
Understanding Immune Resistance at the Molecular Level
12:30 p.m. LUNCH AND POSTER VIEWING
Genetic Engineering of the Immune Systems
1:30 p.m. Malcolm Brenner, Baylor College of Medicine, Houston, TX
Extending Chimeric Antigen Receptor T Cell Therapy to Solid Tumors
2:00 p.m. James Kochenderfer, National Cancer Institute, Bethesda, MD
Chimeric Antigen Receptors for Treating Hematologic Malignancies
2:30 p.m. Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY
CARs, CCRs and iCARS: A New Class of Drugs for Cancer Immunotherapy
3:00 p.m. Carl June, University of Pennsylvania, Philadelphia, PA
CARs for Leukemia and Beyond
3:30 p.m. BREAK
4:00 p.m. Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, WA
Novel CARs and Cell Compositions for Adoptive Cancer Therapy
4:30 p.m. Crystal Mackall, National Cancer Institute, Bethesda, MD
Chimeric Antigen Receptor Based Therapies for Childhood Cancer
5:00 p.m. Laurence Cooper, MD Anderson Cancer Center, Houston, TX
Genetically Modifying with Transposons and Genetically Editing with Artificial Nucleases to Engineer T Cells for Human Application

Friday, October 10

Checkpoint Modulators
8:30 a.m. Suzanne Topalian, Johns Hopkins University, Baltimore, MD
PD-1 Pathway Blockade in Cancer Therapy
9:00 a.m. Jedd Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY
Anti-CTLA-4 Based Combinatorial Immunotherapeutic Strategies
9:30 a.m. Stephen Hodi, Dana Farber Cancer Institute, Boston, MA
Cytokines and Anti-angiogenesis Combinations with Immune Checkpoint B lockade
10:00 a.m. James Allison, MD Anderson Cancer Center, Houston, TX
Immune Checkpoint Blockade in Cancer Therapy: New Insights
10:30 a.m. BREAK
Other Approaches to Cancer Immunotherapy
11:00 a.m. Dan Fowler, National Cancer Institute, Bethesda, MD
Allogeneic T-Rapamycin Cell Therapy of Refractory Lymphoma
11:30 a.m. Jeffrey Miller, University of Minnesota, Minneapolis, MN
Educating and Targeting NK Cells in vivo to Exploit their Activity for Cancer and Transplantation Therapy
12:00 p.m. Ronald Levy, Stanford University, Stanford, CA
Targeting the Tumor and Targeting the Host
12:30 p.m. LUNCH AND POSTER VIEWING
2:00 p.m. Thomas Waldmann, National Cancer Institute, Bethesda, MD
The Evil Face of Janus Kinases: Disorders of Gamma Cytokines, JAKs and STATS in T-cell Malignancies
2:30 p.m. Jeffrey Schlom, National Cancer Institute, Bethesda, MD
Emerging Concepts in the Design and Development of Recombinant Cancer Vaccines
3:00 p.m. James Yang, National Cancer Institute, Bethesda, MD
Immunotherapy of Renal Cell Cancer
3:30 - 5:00 p.m. Poster viewing
General Information

For conference related questions please contact Deborah Bearor at 301-228-4027

Location


Masur and Lipsett Auditorium, Blg 10
NIH - Bethesda, MD

Spacer Image
Bottom Conference Border